Necrosis Predicts Benefit from Hypoxia-modifying Therapy in Patients with High Risk Bladder Cancer Enrolled in a Phase III Randomised Trial

Overview

Journal Radiother Oncol

Specialties Oncology
Radiology

Date 2013 Jun 19

PMID 23773411

Citations 23

Authors

Amanda Eustace

Joely J Irlam

Janet Taylor

Helen Denley

Shailesh Agrawal

Ananya Choudhury

David Ryder

Jonathan J Ord

Adrian L Harris

Ana M Rojas

Peter J Hoskin

Catharine M L West

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Addition of carbogen and nicotinamide (hypoxia-modifying agents) to radiotherapy improves the survival of patients with high risk bladder cancer. The study investigated whether histopathological tumour features and putative hypoxia markers predicted benefit from hypoxia modification.

Materials And Methods: Samples were available from 231 patients with high grade and invasive bladder carcinoma from the BCON phase III trial of radiotherapy (RT) alone or with carbogen and nicotinamide (RT+CON). Histopathological tumour features examined were: necrosis, growth pattern, growing margin, and tumour/stroma ratio. Hypoxia markers carbonic anhydrase-IX and glucose transporter-1 were examined using tissue microarrays.

Results: Necrosis was the only independent prognostic indicator (P=0.04). Necrosis also predicted benefit from hypoxia modification. Five-year overall survival was 48% (RT) versus 39% (RT+CON) (P=0.32) in patients without necrosis and 34% (RT) versus 56% (RT+CON) (P=0.004) in patients with necrosis. There was a significant treatment by necrosis strata interaction (P=0.001 adjusted). Necrosis was an independent predictor of benefit from RT+CON versus RT (hazard ratio [HR]: 0.43, 95% CI 0.25-0.73, P=0.002). This trend was not observed when there was no necrosis (HR: 1.64, 95% CI 0.95-2.85, P=0.08).

Conclusions: Necrosis predicts benefit from hypoxia modification in patients with high risk bladder cancer and should be used to select patients; it is simple to identify and easy to incorporate into routine histopathological examination.

Citing Articles

Implementation of Oxygen Enhanced Magnetic Resonance Imaging (OE-MRI) and a Pilot Genomic Study of Hypoxia in Bladder Cancer Xenografts.

Shabbir R, Telfer B, Dickie B, Reardon M, Babur M, Williams K Cancer Genomics Proteomics. 2024; 21(4):380-387.

PMID: 38944425 PMC: 11215426. DOI: 10.21873/cgp.20455.

Digital spatial profiling of the microenvironment of muscle invasive bladder cancer.

Eyers M, Irlam J, Marshall G, Smith V, Baker A, Frost L Commun Biol. 2024; 7(1):737.

PMID: 38890455 PMC: 11189454. DOI: 10.1038/s42003-024-06426-9.

Low CD8 T Cell Counts Predict Benefit from Hypoxia-Modifying Therapy in Muscle-Invasive Bladder Cancer.

Smith V, Mukherjee D, Tsakiroglou A, Baker A, Mistry H, Choudhury A Cancers (Basel). 2023; 15(1).

PMID: 36612036 PMC: 9817934. DOI: 10.3390/cancers15010041.

How the histological structure of some lung cancers shaped almost 70 years of radiobiology.

Worth K, Papandreou I, Hammond E Br J Cancer. 2022; 128(3):407-412.

PMID: 36344595 PMC: 9938174. DOI: 10.1038/s41416-022-02041-9.

Identifying a hypoxia related score to predict the prognosis of bladder cancer: a study with The Cancer Genome Atlas (TCGA) database.

Zhang Z, Li Q, Li A, Wang F, Li Z, Meng Y Transl Androl Urol. 2022; 10(12):4353-4364.

PMID: 35070817 PMC: 8749062. DOI: 10.21037/tau-21-569.

References

McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G . Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005; 97(16):1180-4. DOI: 10.1093/jnci/dji237. View

Janssens G, Rademakers S, Terhaard C, Doornaert P, Bijl H, van den Ende P . Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. J Clin Oncol. 2012; 30(15):1777-83. DOI: 10.1200/JCO.2011.35.9315. View

Kaanders J, Wijffels K, Marres H, Ljungkvist A, Pop L, van den Hoogen F . Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res. 2002; 62(23):7066-74. View

Koukourakis M, Bentzen S, Giatromanolaki A, Wilson G, Daley F, Saunders M . Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol. 2006; 24(5):727-35. DOI: 10.1200/JCO.2005.02.7474. View

Mesker W, Liefers G, Junggeburt J, van Pelt G, Alberici P, Kuppen P . Presence of a high amount of stroma and downregulation of SMAD4 predict for worse survival for stage I-II colon cancer patients. Cell Oncol. 2009; 31(3):169-78. PMC: 4618830. DOI: 10.3233/CLO-2009-0478. View

Overgaard J, Eriksen J, Nordsmark M, Alsner J, Horsman M . Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol. 2005; 6(10):757-64. DOI: 10.1016/S1470-2045(05)70292-8. View

Thrall D, Rosner G, Azuma C, McEntee M, Raleigh J . Hypoxia marker labeling in tumor biopsies: quantification of labeling variation and criteria for biopsy sectioning. Radiother Oncol. 1997; 44(2):171-6. DOI: 10.1016/s0167-8140(97)01931-2. View

Iakovlev V, Pintilie M, Morrison A, Fyles A, Hill R, Hedley D . Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX. Lab Invest. 2007; 87(12):1206-17. DOI: 10.1038/labinvest.3700680. View

Hoskin P, Sibtain A, Daley F, Wilson G . GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON. Br J Cancer. 2003; 89(7):1290-7. PMC: 2394309. DOI: 10.1038/sj.bjc.6601260. View

10.

Remzi M, Haitel A, Margulis V, Karakiewicz P, Karakiewizc P, Montorsi F . Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int. 2008; 103(3):307-11. DOI: 10.1111/j.1464-410X.2008.08003.x. View

11.

Toustrup K, Sorensen B, Nordsmark M, Busk M, Wiuf C, Alsner J . Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res. 2011; 71(17):5923-31. DOI: 10.1158/0008-5472.CAN-11-1182. View

12.

Moorman A, Vink R, Heijmans H, van der Palen J, Kouwenhoven E . The prognostic value of tumour-stroma ratio in triple-negative breast cancer. Eur J Surg Oncol. 2012; 38(4):307-13. DOI: 10.1016/j.ejso.2012.01.002. View

13.

Rodel C, Grabenbauer G, Kuhn R, Papadopoulos T, Dunst J, Meyer M . Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002; 20(14):3061-71. DOI: 10.1200/JCO.2002.11.027. View

14.

Hoff C, Sand Hansen H, Overgaard M, Grau C, Johansen J, Bentzen J . The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy--results from the randomized DAHANCA 5 study. Radiother Oncol. 2010; 98(1):28-33. DOI: 10.1016/j.radonc.2010.09.024. View

15.

Harris A . Hypoxia--a key regulatory factor in tumour growth. Nat Rev Cancer. 2002; 2(1):38-47. DOI: 10.1038/nrc704. View

16.

Bussink J, van der Kogel A, Kaanders J . Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol. 2008; 9(3):288-96. DOI: 10.1016/S1470-2045(08)70073-1. View

17.

Toustrup K, Sorensen B, Lassen P, Wiuf C, Alsner J, Overgaard J . Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol. 2011; 102(1):122-9. DOI: 10.1016/j.radonc.2011.09.010. View

18.

de Kruijf E, van Nes J, van de Velde C, Putter H, Smit V, Liefers G . Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res Treat. 2010; 125(3):687-96. DOI: 10.1007/s10549-010-0855-6. View

19.

Youssef R, Lotan Y . Predictors of outcome of non-muscle-invasive and muscle-invasive bladder cancer. ScientificWorldJournal. 2011; 11:369-81. PMC: 5733251. DOI: 10.1100/tsw.2011.28. View

20.

Kruger S, Noack F, Bohle A, Feller A . Histologic tumor growth pattern is significantly associated with disease-related survival in muscle-invasive transitional cell carcinoma of the urinary bladder. Oncol Rep. 2004; 12(3):609-13. View